Hemostasis Reference Lab

Phone: 800-245-3117 x6250 | Fax 414-937-6184



NOTE: Versiti does NOT bill patients or insurance. Test orders must be placed through a medical facility that has an account with Versiti. Client # required.

Ordering Institution Information						
Person Completing Requisition:		Physician/Provider:				
Institution:		•			Client #:	
Dept:	Addre	Address:				
City:			State: Zip			Code:
Phone (Lab):	Provider Cont	er Contact (phone/email):				
Special Reporting Requests:					PO #:	
Is testing for outpatient Medicare enrollee or Wisconsin Medicaid recipient? \square Yes \square No If yes, please complete the beneficiary form located at https://versiti.org/products-services/requisitions and submit with this requisition.						
Patient Information						
Last Name:		First Name:			MI:	DOB:
MR#:	Accession #:	ion #:		Draw Date:		Draw Time:
Biologic Sex/Sex Assigned at Birth: ☐Male ☐Female ☐Other Clinical Diagnosis:						
Specimen Information						
- 11	rated Plasma	EDTA Blood (Serum (red top)		Citrated Blood
Test Orders PLEASE COMPLETE HISTORY AND MEDICATION LIST ON REVERSE SIDE FOR AN INTERPRETATION						
Bleeding Disorders						
Hemophilia	105)		T	: (1126)	—	(4.1)
☐ Factor VIII Activity-Chromogenic (1135) ☐ Factor VIII Activity Hepzyme Treated-Chromogenic (1136) ☐ Factor IX Activity (1091)						
☐ Factor VIII Inhibitor (1137) ☐ Factor VIII Inhibitor Hepzyme Treated (1138) ☐ Factor IX Inhibitor (1095) ☐ Factor VIII Activity-Clot Based (1081) ☐ Factor VIII Activity Hepzyme Treated-Clot Based (1082) ☐ Factor VIII Activity Hepzyme Treated (1138) ☐ Factor VIII Activity Hepzyme Treated (1138) ☐ Factor VIII Activity Hepzyme Treated (1138) ☐ Factor IX Inhibitor (1095)						
Is the patient on emicizumab? Is the patient on emicizumab?						
□ Porcine Factor VIII Inhibitor Profile (1086)² □ Porcine Factor VIII Inhibitor Profile (1084)² □ Factor IX Inhibitor-Hepzyme Treated (1094)						
von Willebrand Disease						
Evaluations and Profiles:						
□ VWD Diagnostic Evaluation ² (1800) Follows reflexive algorithm □ VWF Collagen Binding Profile ² (1279)						
□ VWD Type 2B Evaluation ² (1067) □ VWD Type 2N Profile ² (1088) Individual Tests:						
WWF Antigen (1062) □ VWF Quantitative Multimer (1063) □ VWF Collagen III Binding (1281) □ VWD Type 2N (1089)						
☐ VWF GP1bM Activity¹ (1070)	e Antigen (1282)					
☐ Anti-VWF Antibody IgG and IgM (1056)						
Special Coagulation						
☐ Arixtra® (Fondaparinux) Level (1009) ☐ Factor VII Activity (1071) ☐ Factor XII Activity (1121)						ctivity (1121)
☐ Factor II Activity (1021)	☐ Factor VII Inhibi	* * * *				
□ Factor II Inhibitor (1025) □ Factor X Activity (1101)				☐ Fibrinogen Activity (1011)		
☐ Factor V Activity (1051)	r (1105)					
☐ Factor V Inhibitor (1055)	☐ Factor XI Activit	, , ,			nduced Platelet Aggregation ³ (1068)	
□ Platelet Aggregations³ (1175) □ Factor XI Inhibitor (1115)						
Clotting Disorders						
Thrombotic Microangiopathy						
Evaluations and Profiles:						
□ ADAMTS13 Evaluation ² (1295) <i>Follows reflexive algorithm</i> □ aHUS Complement Profile ² (1500)						
Individual ADAMTS13 Tests:						
□ ADAMTS13 Activity (1298) □ ADAMTS13 Inhibitor (1297) □ ADAMTS13 Antibody (1299)						.3 Antibody (1299)
Individual aHUS Complement Tests:						
□ C3 (1501)	☐ C4 (1502)		□ C46 (MCP) Expression (150	7)	☐ Factor B (1503)
☐ Factor H (1505)	☐ Factor H Antibod	y (1506)	☐ Facto	or I (1504)		
Thrombophilia						
☐ Protein C Activity¹ (1031) ☐ Protein S Activi					Antigen Total & Free (1042)	
☐ Protein C Antigen (1033)	otein S Antigen Fr					
¹ For local STAT testing, please call 800					VERSITI USE ONLY	
² See reverse side for assays included i	orofiles			EDTACITPACBDACDA		
³ By appointment only. Please call 800-245-3117 x 6129 to schedule.						Serum Clot Other
						
For genetic testing, please use Hematology Genetics Requisition.					Оре	ened by: Evaluated by:

PATIENT HAS TAKEN THE FOLLOWING ANTICOAGULANTS IN THE LAST 10 DAYS (check all that apply): ☐ Unfractionated Heparin ☐ Low Molecular Weight Heparin □ Warfarin □ Dabigatran □ Apixaban ☐ Rivaroxaban □ Edoxaban ☐ Other PLEASE PROVIDE THE FOLLOWING LAB HISTORY/PHENOTYPE OF PATIENT: \/****/F VWF VWF: RCo \/\//E F\/III FIX ADAMTS13 ADAMTS13 **Platelet** Other Other Inhibitor Antigen Activity Activity Multimer Activity Activity Count Activity Date Date PLEASE PROVIDE PATIENT'S FAMILY LAB HISTORY/PHENOTYPE: Relation VWF VWF: RCo VWF VWF FVIII FIX Platelet ADAMTS13 ADAMTS13 Other to patient Antigen Activity Activity Multimer Activity Activity Count Activity Inhibitor Date

SUGGESTED EVALUATIONS AND PROFILES

ADDITIONAL COMMENTS:

ADAMTS13 Evaluation – Follows a reflexive algorithm. Activity is always performed. If </= 30, inhibitor is performed. If inhibitor </= 0.7, antibody is performed.

aHUS Complement Profile includes C3, C4, CD46 (MCP) Expression, Factor B, Factor H, Factor H Autoantibody, and Factor I.

Porcine Factor VIII Inhibitor Profile includes Factor VIII Activity and Porcine Factor VIII Inhibitor, hepzyme treated if indicated by order.

VWD Diagnostic Evaluation Follows a reflexive algorithm, always includes: FVIII Activity, VWF Antigen, VWF GPIbM Activity, and VWF Collagen III Binding. Reflex testing may include: VWF Propeptide Antigen, VWF Quantitative Multimer, VWD Type 2N Binding and/or VWD Type 2B Binding.

VWD Type 2B Evaluation includes VWD Type 2B Binding and VWF Quantitative Multimer.

VWD Type 2N Profile includes FVIII Activity, VWF Antigen, and VWD Type 2N Binding.

VWF Collagen Binding Profile includes VWF Antigen, VWF Collagen III Binding and VWF Collagen IV Binding. Additional reflex to VWF Quantitative Multimer, if indicated.

SHIPPING INFORMATION

PATIENT HISTORY:

Date

Blood samples should be shipped by overnight carrier. The package must be shipped in compliance with carrier's guidelines. Please contact your carrier for current biohazardous shipping regulations. Label Box: Refrigerate, Room Temperature, or Frozen (whichever is appropriate)

Packages should be addressed to:

Versiti Wisconsin – Client Services 638 N 18th Street Milwaukee, WI 53233